DOCSLIB.ORG

Combined Estrogen–Progestogen Menopausal Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Estrogen–Progestogen Menopausal Therapy COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem. Abstr. Serv. Reg. No.: 427-51-0 molecular mass H C Chem. Abstr. Name: (1β,2β)-17- 3 OH ′ CH2 (Acetyloxy)-6-chloro-1,2-dihydro-3 H- H C cyclopropa[1,2]pregna-1,4,6-triene-3,20- 2 C CH dione H H IUPAC Systematic Name: 6-Chloro-1β,2β- dihydro-17-hydroxy-3′H-cyclopropa[1,2] HH pregna-1,4,6-triene-3,20-dione acetate Synonyms: Cyproterone 17-O-acetate; cyproterone 17α-acetate; 1,2α-methylene- C H O 6-chloro-17α-acetoxy-4,6-pregnadiene- 22 30 Relative molecular mass: 310.5 3,20-dione; 1,2α-methylene-6-chloro-Δ4,6- pregnadien-17α-ol-3,20-dione acetate; (d) Drospirenone 1,2α-methylene-6-chloro-pregna-4,6- diene-3,20-dione 17α-acetate; methylene- Chem. Abst. Services Reg. No.: 67392-87-4 6-chloro-17-hydroxy-1α,2α-pregna-4,6- Chem. Abstr. Name: (2′S,6R,7R,8R,9S,10R,- diene-3,20-dione acetate 13S,14S,15S,16S)-1,3′,4′,6,7,8,9,10,11,- 12,13,14,15,16,20,21-Hexadecahydro Structural and molecular formulae, and relative -10,13-dimethyl-spiro[17H-dicyclop molecular mass ropa[6,7:15,16]cyclopenta[a]phenan- O CH3 threne-17,2′ (5′H)-furan]-3,5′ (2H)-dione C CH3 CH3 Synonyms: Dihydrospirorenone; 1,2-di- O C hydrospirorenone; drospirenona; spiro[17H-dicyclopropa[6,7:15,16] CH3 H O cyclopenta[a]phenanthrene-17,2′(5′H)- furan]-3,5′(2H)-dione, 1,3′,4′,6,7,8,9,10,11 HH ,12,13,14,15,16,20,21-hexadecahydro-10,13- O dimethyl-, [6R-(6α,7α,8β,9α,10β,13β,14α,1 Cl 5α,16α,17β)]- Structural and molecular formulae, and relative C H ClO 24 29 4 molecular mass Relative molecular mass: 416.9 O (c) Desogestrel H C Chem. Abstr. Serv. Reg. No.: 54024-22-5 3 O Chem. Abstr. Name: (17α)-13-Ethyl-11- methylene-18,19-dinorpregn-4-en-20-yn- CH3 H 17-ol IUPAC Systematic Name: 13-Ethyl-11- HH methylene-18,19-dinor-17α-pregn-4-en- 20-yn-17-ol O Synonyms: 13-Ethyl-11-methylene- 18,19-dinor-17α-4-pregnen-20-yn-17-ol; C24H30O3 17α-ethynyl-18-methyl-11-methylene-Δ4- Relative molecular mass: 366.5 oestren-17β-ol 250 Combined estrogen-progestogen menopausal therapy (e) Dydrogesterone (g) Gestodene Chem. Abstr. Serv. Reg. No.: 152-62-5 Chem. Abstr. Serv. Reg. No.: 60282-87-3 Chem. Abstr. Name: (9β,10α)-Pregna-4,6- Deleted CAS Reg. No.: 110541-55-4 diene-3,20-dione Chem. Abstr. Name: (17α)-13-Ethyl-17- IUPAC Systematic Name: 10α-Pregna-4,6- hydroxy-18,19-dinorpregna-4,15-dien-20- diene-3,20-dione yn-3-one Synonyms: 10α-Isopregnenone; dehydro- IUPAC Systematic Name: 13-Ethyl-17- retroprogesterone; dehydroprogesterone hydroxy-18,19-dinor-17α-pregna-4,15- Structural and molecular formulae, and relative dien-20-yn-3-one molecular mass Structural and molecular formulae, and relative O molecular mass CH3 C H 3C CH3 OH CH2 C CH CH H 3 H H H H H H O O C21H28O2 C21H26O2 Relative molecular mass: 312.5 Relative molecular mass: 310.4 (f) Ethynodiol diacetate (h) Levonorgestrel Chem. Abstr. Serv. Reg. No.: 297-76-7 Chem. Abstr. Name: (3β,17α)-19-Norpregn- Chem. Abstr. Serv. Reg. No.: 797-63-7 4-en-20-yne-3,17-diol, diacetate Deleted CAS Reg. No.: 797-62-6; 4222-79-1; IUPAC Systematic Name: 19-Nor-17α- 121714-72-5 pregn-4-en-20-yne-3β,17β-diol, diacetate Chem. Abstr. Name: (17α)-13-Ethyl-17- Synonyms: Ethinodiol diacetate; ethynodiol hydroxy-18,19-dinorpregn-4-en-20-yn-3- acetate; β-ethynodiol diacetate one IUPAC Systematic Name: 13-Ethyl-17- Structural and molecular formulae, and relative hydroxy-18,19-dinor-17α-pregn-4-en-20- molecular mass yn-3-one O Synonyms: 13-Ethyl-17-ethynyl- O C CH3 17β-hydroxy-4-gonen-3-one; CH3 C CH 13-ethyl-17α-ethynyl-17- hydroxygon-4-en-3-one; 13-ethyl-17α- H H ethynylgon-4-en-17β-ol-3-one; 13β-ethyl- H H 17α-ethynyl-17β-hydroxygon-4-en-3-one; O 13-ethyl-17-hydroxy-18,19-dinor-17α- C CH O 3 H pregn-4-en-20-yn-3-one; 17-ethynyl- 18-methyl-19-nortestosterone; 18-methyl- C24H32O4 norethindrone; l-norgestrel; dl-norgestrel; Relative molecular mass: 384.5 d-norgestrel 251 IARC MONOGRAPHS – 100A Structural and molecular formulae, and relative (j) Medroxyprogesterone acetate molecular mass Chem. Abstr. Serv. Reg. No.: 71-58-9 H C Chem. Abstr. Name: (6α)-17-(Acetyloxy)-6- 3 OH CH2 methylpregn-4-ene-3,20-dione C CH IUPAC Systematic Name: 17-Hydroxy-6α- H H methylpregn-4-ene-3,20-dione, acetate Synonyms: 17α-Acetoxy-6α- H H methylprogesterone; depomedroxypro- gesterone acetate; depo-progestin; depot- O medroxyprogesterone acetate; DMPA; C H O 17-hydroxy-6α-methylprogesterone, ac- 21 28 2 etate; 17α-hydroxy-6α-methylprogesterone Relative molecular mass: 312.5 acetate; MAP; MPA; medroxypro- (i) Lynestrenol gesterone 17-acetate; 6α-methyl-17- acetoxyprogesterone; 6α-methyl-17α- Chem. Abstr. Serv. Reg. No.: 52-76-6 hydroxyprogesterone acetate Deleted CAS Reg. No.: 60416-16-2 Chem. Abstr. Name: (17α)-19-Norpregn-4- Structural and molecular formulae, and relative en-20-yn-17-ol molecular mass IUPAC Systematic Name: 19-Nor-17α- O CH3 C pregn-4-en-20-yn-17-ol CH CH 4 3 3 Synonyms: 3-Desoxynorlutin; Δ - O C 17α-ethinylestren-17β-ol; Δ4-17α- CH H ethinyloestren-17β-ol; ethynylestrenol; 3 O ethynyloestrenol; 17α-ethynylestrenol; 17α-ethynyloestrenol; 17α-ethynyl-17β- H H 4 hydroxy-Δ -estrene; 17α-ethynyl-17β- O hydroxy-Δ4-oestrene H CH3 Structural and molecular formulae, and relative C H O molecular mass 24 34 4 Relative molecular mass: 386.5 OH CH3 (k) Megestrol acetate C CH Chem. Abstr. Serv. Reg. No.: 595-33-5 H H Chem. Abstr. Name: 17-(Acetyloxy)- 6-methylpregna-4,6-diene-3,20-dione H H IUPAC Systematic Name: 17-Hydroxy- 6-methylpregna-4,6-diene-3,20-dione, C H O acetate 20 28 Synonyms: DMAP; megestryl acetate; MGA Relative molecular mass: 284.4 252 Combined estrogen-progestogen menopausal therapy Structural and molecular formulae, and relative (m) Norethisterone acetate molecular mass Chem. Abstr. Serv. Reg. No.: 51-98-9 O CH3 Chem. Abstr. Name: (17α)-17-(Acetyloxy)- C 19-norpregn-4-en-20-yn-3-one CH3 CH3 O C IUPAC Systematic Name: 17-Hydroxy-19- nor-17α-pregn-4-en-20-yn-3-one, acetate CH H 3 O Synonyms: 17α-Ethinyl-19-nortestosterone 17β-acetate; 17α-ethinyl-19-nortestosterone H H acetate; 17α-ethynyl-19-nortestosterone O acetate; norethindrone acetate; norethin- drone 17-acetate; norethisteron acetate; CH 3 norethisterone 17-acetate; 19-norethister- one acetate; norethynyltestosterone acetate; C24H32O4 Relative molecular mass: 384.5 19-norethynyltestosterone acetate; nor- ethysterone acetate (l) Norethisterone Structural and molecular formulae, and relative Chem. Abstr. Serv. Reg. No.: 68-22-4 molecular mass Chem. Abstr. Name: (17α)-17-Hydroxy-19- O norpregn-4-en-20-yn-3-one O C CH3 IUPAC Systematic Name: 17-Hydroxy-19- CH3 nor-17α-pregn-4-en-20-yn-3-one C CH Synonyms: Ethinylnortestosterone; H H 17α-ethinyl-19-nortestosterone; ethynyl- nortestosterone; 17-ethynyl-19-nortestos- H H terone; 17α-ethynyl-19-nortestosterone; O norethindrone; norethisteron; norethyno- drone; 19-nor-17α-ethynyltestosterone; C H O norpregneninolone 22 28 3 Relative molecular mass: 340.5 Structural and molecular formulae, and relative molecular mass (n) Norethisterone enanthate OH Chem. Abstr. Serv. Reg. No.: 3836-23-5 CH3 Chem. Abstr. Name: (17α)-17-(Heptanoyl)- C CH 19-norpregn-4-en-20-yn-3-one H H IUPAC Systematic Name: 17-Hydroxy-19- nor-17α-pregn-4-en-20-yn-3-one, heptano- H H ate O Synonyms: Norethindrone enanthate; norethindrone oenanthate; norethister- C20H26O2 one enanthate; norethisterone heptanoate; Relative molecular mass: 298.4 17β-hydroxy-19-nor-17α-pregn-4-en-20- yn-3-one heptanoate 253 IARC MONOGRAPHS – 100A Structural and molecular formulae, and relative Structural and molecular formulae, and relative molecular mass molecular mass O O H 3C O C (CH2)5 CH3 O C CH3 CH3 CH2 C CH C CH H H H H H H H H O HO N C27H38O3 C23H31NO3 Relative molecular mass: 410.6 Relative molecular mass: 369.5 (o) Norethynodrel (q) Norgestrel Chem.
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The Progestogen Only Pill
    The Progestogen Only Pill Mini-pill or POP A service provided by page 2 of 8 How does the progestogen only pill (POP) work? The progestogen only pill mainly works by thickening the mucus you produce from your cervix. This makes it more difficult for sperm to get to the egg. It can also sometimes stop your ovaries from producing an egg (ovulation). How effective is the pill? The effectiveness of the pill depends on the woman taking it. At best it is over 98% effective (when no pills are missed). However failure rates can be much higher (9-15%) if women do not remember to take their pill properly. Missed pills can lead to pregnancy. Advantages of the POP • It doesn’t interfere with sex. • You can use it whilst you are breastfeeding. • It is useful if you cannot take oestrogen (the hormone contained in the combined oral contraceptive) • Can be used at any age even if you smoke and are over 35 years of age. • It may help with premenstrual symptoms and painful periods. page 3 of 8 Disadvantages of the POP • You have to remember to take your pill at the same time every day. • Your periods may become irregular or even stop altogether on the POP, this is not dangerous but if you miss a period you need to check that you are not pregnant by coming to clinic for a pregnancy test. • You may get some temporary side effects, such as spotty skin, breast tenderness and mood changes, though these should stop within a few months.
    [Show full text]
  • Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes
    EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice.
    [Show full text]
  • Affect Breast Cancer Risk
    HOW HORMONES AFFECT BREAST CANCER RISK Hormones are chemicals made by the body that control how cells and organs work. Estrogen is a female hormone made mainly in the ovaries. It’s important for sexual development and other body functions. From your first monthly period until menopause, estrogen stimulates normal breast cells. A higher lifetime exposure to estrogen may increase breast cancer risk. For example, your risk increases if you start your period at a young age or go through menopause at a later age. Other hormone-related risks are described below. Menopausal hormone therapy Pills Menopausal hormone therapy (MHT) is The U.S. Food and Drug Administration also known as postmenopausal hormone (FDA) recommends women use the lowest therapy and hormone replacement dose that eases symptoms for the shortest therapy. Many women use MHT pills to time needed. relieve hot flashes and other menopausal Any woman currently taking or thinking symptoms. MHT should be used at the Birth control about taking MHT pills should talk with her lowest dose and for the shortest time pills (oral doctor about the risks and benefits. contraceptives) needed to ease menopausal symptoms. Long-term use can increase breast cancer Vaginal creams, suppositories Current or recent use risk and other serious health conditions. and rings of birth control pills There are 2 main types of MHT pills: slightly increases breast Vaginal forms of MHT do not appear to cancer risk. However, estrogen plus progestin and estrogen increase the risk of breast cancer. However, this risk is quite small alone. if you’ve been diagnosed with breast cancer, vaginal estrogen rings and suppositories are because the risk of Estrogen plus progestin MHT breast cancer for most better than vaginal estrogen creams.
    [Show full text]
  • Informed Consent for Feminizing Hormone Therapy
    Informed Consent for Feminizing Hormone Therapy For _________________________ Date of Birth: _____________ Name Used: ____________________ Patient Name as listed in chart Name if different from chart This form will assist you (and your guardian) to think through the expected effects of hormone therapy including possible unwanted side effects. You are encouraged to talk about this treatment with your medical provider and decide if hormone therapy is right for you (your child). By signing this form, you are stating that you have discussed the effects and risks of this medication with your medical provider or a member of the medical team and that you understand and accept these effects and possible risks. You (and your guardian) may ask questions and talk about any concerns you have related to this treatment at any time in this process. Estrogen (usually estradiol) is used to feminize the body (make it look more traditionally female). This medical treatment will reduce some male features and increase some female features of the body. Androgen (testosterone) blockers further decrease the amount of and/or block the effect of testosterone and masculinization of the body. Your medical provider will help decide which form and the amount of estrogen (shots, pills, gels, patches) and androgen blockers (pills, gels, shots, implanted) that are best for you based on your personal needs and any medical or mental health conditions you might have. Each person’s body responds to estrogen differently and it is hard to promise or predict with certainty how each person may respond to treatment. Your medical provider will talk with you throughout the treatment and will help you achieve the best results safely.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Feminizing Hormone Therapy
    FEMINIZING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health April 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical treatment ▪ WPATH criteria
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • WHO Statement on Progestogen-Only Implants
    WHO statement on Progestogen-only implants Key facts Progestogen-only implants consist of hormone-filled capsules or rods that are inserted under the skin in a woman’s upper arm The purpose of this Statement is to reiterate and Life-Saving Commodities for Women and Children clarify the existing (current) WHO position based on endorsed contraceptive implants as one of its 13 Life- published guidance that is still valid. WHO monitors Saving Commodities. the evidence in this field closely and will update Primary mechanisms of action of the implants include its guidance as and when new evidence becomes thickening cervical mucus (making it difficult for available. sperm to penetrate) and preventing ovulation in KEY FACTS ABOUT PROGESTOGEN-ONLY IMPLANTS about half of menstrual cycles. Long-acting reversible contraceptives, including USE OF PROGESTOGEN-ONLY IMPLANTS BY intrauterine devices and implants are the most WOMEN LIVING WITH HIV effective methods of reversible contraception. These There have been concerns from recent publications methods have multiple advantages over other regarding the effectiveness of progestogen-only reversible methods. Most importantly, once in place, implants among women living with HIV and on they do not require daily or monthly dosing and their some antiretroviral drugs.1 However, compared with duration of contraceptive action ranges from 3 to 5 other hormonal methods, no significant differences years. in pregnancy rates have been observed with Progestogen-only implants consist of hormone-filled progestogen-only implants.2 capsules or rods that are inserted under the skin of a woman’s upper arm. Current systems consist of one or two rods.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]